Dr. Hyojeong Han

Meghan Delaney, DO, MPH, is the chief of the Division of Pathology and Lab Medicine and director of Transfusion Medicine. She is the professor of Pathology and Pediatrics and the George Washington University. Dr. Delaney serves as a member of the Board of Directors for the Association for the Advancement of Blood & Biotherapies (AABB), a scientific member of the BEST Collaborative and member of the American Board of Pathology Test Development and Advisory Committee. Dr. Delaney’s scholarly focus is in clinical pathology, laboratory management, transfusion medicine, pediatric transfusion medicine and immunohematology. She has over 100 peer reviewed publications and lectures nationally and internationally. In global health, Dr. Delaney focuses on improving access to safe blood transfusion in developing nations. She serves as the Chair of NIH’s BLOODSAFE Program that aims to improve access to safe blood in Sub Saharan Africa. The British Blood Transfusion Society (BBTS) recognized Dr. Delaney with the 2021 James Blundell Award. This is the most prestigious award given by the BBTS. Introduced in 1984, this award is given to recipients for original research resulting in an important and significant contribution to the body of medical and or scientific knowledge within the field of blood transfusion. Dr. Delaney is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Hemolytic Disease of the Newborn, Anemia, Multisystem Inflammatory Syndrome in Children (MIS-C), and Kawasaki Disease. Dr. Delaney is board certified in Blood Banking/Transfusion Medicine: American Board Of Pathology, 2008 and Clinical Pathology: American Board Of Pathology, 2007.

Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program at Children’s National Hospital. She also serves as an associate professor of pediatrics at George Washington University. Dr. Meany is dedicated to finding better treatments for children with cancer through research and clinical care. Her work focuses on developing new therapies for pediatric solid tumors. She designs and leads early-phase clinical trials to test promising treatments and understand how they work in children. Dr. Meany has played a key role in several national studies, including large trials for neuroblastoma, a type of childhood cancer. She recently led an international study for children with newly diagnosed non-high-risk neuroblastoma and is currently helping to develop the next high-risk neuroblastoma trial, both through the Children’s Oncology Group. Dr. Meany is also exploring innovative approaches like immunotherapy—using the body’s own immune system to fight cancer. She has led international studies using specialized T cells to treat patients with relapsed solid tumors and is now working on combining these novel T cells with CAR T-cell therapy for children with relapsed cancers. In addition to her research, Dr. Meany is passionate about training the next generation of pediatric cancer specialists. As director of the Pediatric Hematology-Oncology Fellowship Program at Children’s National, she mentors and supports future leaders in the field. Dr. Meany is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, and Mastoidectomy. Dr. Meany is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Urania Dagalakis, MD, MHSc, specializes in pediatric oncology and hematology. She completed her clinical training at Johns Hopkins University and conducted her research work within the National Cancer Institute of the National Institutes of Health. Due to her research background she specializes in caring for children with rare tumors and hereditary cancer syndromes. Dr. Dagalakis is the director of the Cancer Genetics Clinic at Children’s National Hospital. She is also an assistant professor of pediatrics at The George Washington University School of Medicine and Health Sciences and a physician in the Center for Cancer and Blood Disorders. She is committed to empowering families with knowledge, supporting survivorship and leading innovations in personalized cancer care. Her work bridges compassionate patient care with clinical research focused on improving outcomes for children with genetic cancer predispositions. Dr. Dagalakis is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hemoglobin SC Disease and Immune Thrombocytopenic Purpura (ITP). Dr. Dagalakis is board certified in Pediatrics: American Board Of Pediatrics, 2023.

Lea Mayer is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Mayer is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Hereditary Neuroblastoma, Neuroblastoma, Ewing Sarcoma, and Osteosarcoma. Dr. Mayer is board certified in Oncology Nursing Certification Corporation, 2015 and Primary Care Certified Pediatric Nurse Practitioner (CPNP-PC): Pediatric Nursing Certification Board, 2010.

Luca Szalontay is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Szalontay is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Brain Stem Cancer. Dr. Szalontay is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021 and Pediatrics: American Board Of Pediatrics, 2015. Dr. Szalontay is currently accepting new patients.

Ashley Lanzel, MD, MA, trained in pediatrics at Johns Hopkins Hospital, pediatric hematology-oncology at Emory/Children’s Healthcare of Atlanta, and hospice and palliative medicine at the National Institutes of Health. While at Emory University, she obtained a Master of Arts in bioethics. Her research focus is in decision-making, communication, palliative oncology and pediatric palliative ethics. She enjoys being a clinical educator. When she is not at work, she is having fun with her kids. Her clinical expertise encompasses GM1 Gangliosidosis. Dr. Lanzel is board certified in American Board Of Pediatrics, 2022, Pediatrics: American Board Of Pediatrics, 2015, and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2019.